Kiniksa Pharmaceuticals Stock Probability Of Bankruptcy
| KNSA Stock | USD 21.80 0.52 2.44% |
Kiniksa | Probability Of Bankruptcy |
Kiniksa Pharmaceuticals Company chance of distress Analysis
Kiniksa Pharmaceuticals' Probability Of Bankruptcy is a relative measure of the likelihood of financial distress. For stocks, the Probability Of Bankruptcy is the normalized value of Z-Score. For funds and ETFs, it is derived from a multi-factor model developed by Macroaxis. The score is used to predict the probability of a firm or a fund experiencing financial distress within the next 24 months. Unlike Z-Score, Probability Of Bankruptcy is the value between 0 and 100, indicating the firm's actual probability it will be financially distressed in the next 2 fiscal years.
More About Probability Of Bankruptcy | All Equity Analysis
Probability Of Bankruptcy | = | Normalized | | Z-Score |
Current Kiniksa Pharmaceuticals Probability Of Bankruptcy | Less than 6% |
Most of Kiniksa Pharmaceuticals' fundamental indicators, such as Probability Of Bankruptcy, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Kiniksa Pharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Our calculation of Kiniksa Pharmaceuticals probability of bankruptcy is based on Altman Z-Score and Piotroski F-Score, but not limited to these measures. To be applied to a broader range of industries and markets, we use several other techniques to enhance the accuracy of predicting Kiniksa Pharmaceuticals odds of financial distress. These include financial statement analysis, different types of price predictions, earning estimates, analysis consensus, and basic intrinsic valuation. Please use the options below to get a better understanding of different measures that drive the calculation of Kiniksa Pharmaceuticals financial health.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Kiniksa Pharmaceuticals. If investors know Kiniksa will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Kiniksa Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 5.5 | Earnings Share (0.12) | Revenue Per Share 5.415 | Quarterly Revenue Growth 0.674 | Return On Assets (0.03) |
The market value of Kiniksa Pharmaceuticals is measured differently than its book value, which is the value of Kiniksa that is recorded on the company's balance sheet. Investors also form their own opinion of Kiniksa Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Kiniksa Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Kiniksa Pharmaceuticals' market value can be influenced by many factors that don't directly affect Kiniksa Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Kiniksa Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Kiniksa Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Kiniksa Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Kiniksa Probability Of Bankruptcy Driver Correlations
Understanding the fundamental principles of building solid financial models for Kiniksa Pharmaceuticals is extremely important. It helps to project a fair market value of Kiniksa Stock properly, considering its historical fundamentals such as Probability Of Bankruptcy. Since Kiniksa Pharmaceuticals' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Kiniksa Pharmaceuticals' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Kiniksa Pharmaceuticals' interrelated accounts and indicators.
Click cells to compare fundamentals
The Probability of Bankruptcy SHOULD NOT be confused with the actual chance of a company to file for chapter 7, 11, 12, or 13 bankruptcy protection. Macroaxis simply defines Financial Distress as an operational condition where a company is having difficulty meeting its current financial obligations towards its creditors or delivering on the expectations of its investors. Macroaxis derives these conditions daily from both public financial statements as well as analysis of stock prices reacting to market conditions or economic downturns, including short-term and long-term historical volatility. Other factors taken into account include analysis of liquidity, revenue patterns, R&D expenses, and commitments, as well as public headlines and social sentiment.
| Competition |
Based on the latest financial disclosure, Kiniksa Pharmaceuticals has a Probability Of Bankruptcy of 6.0%. This is 86.14% lower than that of the Biotechnology sector and 89.06% lower than that of the Health Care industry. The probability of bankruptcy for all United States stocks is 84.94% higher than that of the company.
Kiniksa Probability Of Bankruptcy Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Kiniksa Pharmaceuticals' direct or indirect competition against its Probability Of Bankruptcy to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Kiniksa Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Kiniksa Pharmaceuticals by comparing valuation metrics of similar companies.Kiniksa Pharmaceuticals is currently under evaluation in probability of bankruptcy category among its peers.
Kiniksa Pharmaceuticals Main Bankruptcy Drivers
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Return On Assets | (0.64) | (0.46) | (0.68) | 0.4 | 0.0268 | 0.0281 | |
| Net Debt | (44.3M) | (107.1M) | (116.4M) | (116.8M) | (95.7M) | (100.5M) | |
| Total Current Liabilities | 27.8M | 31.8M | 44.8M | 47.1M | 63.7M | 38.2M | |
| Non Current Liabilities Total | 1.3M | 5.7M | 2.9M | 16.5M | 23.8M | 25.0M | |
| Total Assets | 254.5M | 349.5M | 232.8M | 459.7M | 526.3M | 309.2M | |
| Total Current Assets | 241.6M | 333.2M | 196.4M | 243.1M | 276.3M | 234.8M | |
| Total Cash From Operating Activities | (158.4M) | (136.5M) | (126.3M) | 5.8M | 13.3M | 14.0M |
Kiniksa Pharmaceuticals ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Kiniksa Pharmaceuticals' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Kiniksa Pharmaceuticals' managers, analysts, and investors.Environmental | Governance | Social |
Kiniksa Fundamentals
| Return On Equity | -0.0215 | ||||
| Return On Asset | -0.0316 | ||||
| Profit Margin | (0.02) % | ||||
| Operating Margin | (0.09) % | ||||
| Current Valuation | 1.36 B | ||||
| Shares Outstanding | 41.57 M | ||||
| Shares Owned By Insiders | 4.10 % | ||||
| Shares Owned By Institutions | 97.96 % | ||||
| Number Of Shares Shorted | 4.21 M | ||||
| Price To Earning | (7.20) X | ||||
| Price To Book | 3.52 X | ||||
| Price To Sales | 4.10 X | ||||
| Revenue | 270.26 M | ||||
| Gross Profit | 173.21 M | ||||
| EBITDA | (22.86 M) | ||||
| Net Income | 14.08 M | ||||
| Cash And Equivalents | 138.21 M | ||||
| Cash Per Share | 1.99 X | ||||
| Total Debt | 12.26 M | ||||
| Debt To Equity | 0.03 % | ||||
| Current Ratio | 4.13 X | ||||
| Book Value Per Share | 6.06 X | ||||
| Cash Flow From Operations | 13.3 M | ||||
| Short Ratio | 13.50 X | ||||
| Earnings Per Share | (0.12) X | ||||
| Price To Earnings To Growth | 0.25 X | ||||
| Target Price | 36.0 | ||||
| Number Of Employees | 297 | ||||
| Beta | 0.35 | ||||
| Market Capitalization | 1.57 B | ||||
| Total Asset | 526.32 M | ||||
| Retained Earnings | (477.95 M) | ||||
| Working Capital | 212.63 M | ||||
| Current Asset | 54.44 M | ||||
| Current Liabilities | 10.39 M | ||||
| Net Asset | 526.32 M |
About Kiniksa Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Kiniksa Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Kiniksa Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Kiniksa Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Kiniksa Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Kiniksa Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Kiniksa Pharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Kiniksa Pharmaceuticals Stock:Check out Kiniksa Pharmaceuticals Piotroski F Score and Kiniksa Pharmaceuticals Altman Z Score analysis. For information on how to trade Kiniksa Stock refer to our How to Trade Kiniksa Stock guide.You can also try the AI Portfolio Architect module to use AI to generate optimal portfolios and find profitable investment opportunities.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Kiniksa Pharmaceuticals. If investors know Kiniksa will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Kiniksa Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 5.5 | Earnings Share (0.12) | Revenue Per Share 5.415 | Quarterly Revenue Growth 0.674 | Return On Assets (0.03) |
The market value of Kiniksa Pharmaceuticals is measured differently than its book value, which is the value of Kiniksa that is recorded on the company's balance sheet. Investors also form their own opinion of Kiniksa Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Kiniksa Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Kiniksa Pharmaceuticals' market value can be influenced by many factors that don't directly affect Kiniksa Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Kiniksa Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Kiniksa Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Kiniksa Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.